Daniel V Santi

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 13

Top Topics

Structural Basis

Top Venues

Cancer research communications

Bioconjugate chemistry

Cancer chemotherapy and pharmacology

ACS chemical biology

This page only lists publications with an associated author ORCID identifier.

Publications

Christopher W Carreras, Shaun D Fontaine, Ralph R Reid, Gary W Ashley, Daniel V Santi
Long-Acting Poly(ADP-ribose) Polymerase Inhibitor Prodrug for Humans. Bioconjugate chemistry (2024)
Christopher W Carreras, Shaun D Fontaine, Ralph R Reid, Gary W Ashley, Daniel V Santi
Long-Acting Poly(ADP-ribose) Polymerase Inhibitor Prodrug for Humans. Bioconjugate chemistry 35 (4) (2024)
Christopher W Carreras, Shaun D Fontaine, Ralph R Reid, Gary W Ashley, Daniel V Santi
Long-Acting Poly(ADP-ribose) Polymerase Inhibitor Prodrug for Humans. Bioconjugate chemistry 35 (4) (2024)
Shaun D Fontaine, Christopher W Carreras, Ralph R Reid, Gary W Ashley, Daniel V Santi
A Very Long-acting Exatecan and Its Synergism with DNA Damage Response Inhibitors. Cancer research communications 3 (5) (2023)
Shaun D Fontaine, Christopher W Carreras, Ralph R Reid, Gary W Ashley, Daniel V Santi
A Very Long-acting Exatecan and Its Synergism with DNA Damage Response Inhibitors. Cancer research communications 3 (5) (2023)
Shaun D Fontaine, Christopher W Carreras, Ralph R Reid, Gary W Ashley, Daniel V Santi
A Very Long-acting Exatecan and Its Synergism with DNA Damage Response Inhibitors. Cancer research communications 3 (5) (2023)
Shaun D Fontaine, Christopher W Carreras, Ralph R Reid, Gary W Ashley, Daniel V Santi
A Very Long-acting Exatecan and Its Synergism with DNA Damage Response Inhibitors. Cancer research communications 3 (5) (2023)
Shaun D Fontaine, Christopher W Carreras, Ralph R Reid, Gary W Ashley, Daniel V Santi
A Very Long-acting Exatecan and Its Synergism with DNA Damage Response Inhibitors. Cancer research communications 3 (5) (2023)
Anish Thomas, Shaun D Fontaine, Morgan E Diolati, Parth Desai, Rajesh Kumar, Nobuyuki Takahashi, Linda Sciuto, Samantha Nichols, Alan Ashworth, Felix Y Feng, Gary W Ashley, Minh Nguyen, Yves Pommier, Daniel V Santi
PLX038: A Long-Acting Topoisomerase I Inhibitor With Robust Antitumor Activity in ATM-Deficient Tumors and Potent Synergy With PARP Inhibitors. Molecular cancer therapeutics 21 (11) (2022)
Brian R Hearn, Shaun D Fontaine, Eric L Schneider, Yannick Kraemer, Gary W Ashley, Daniel V Santi
Attenuation of the Reaction of Michael Acceptors with Biologically Important Nucleophiles. Bioconjugate chemistry 32 (4) (2021)
Shaun D Fontaine, Byron Hann, Ralph Reid, Gary W Ashley, Daniel V Santi
Species-specific optimization of PEG~SN-38 prodrug pharmacokinetics and antitumor effects in a triple-negative BRCA1-deficient xenograft. Cancer chemotherapy and pharmacology 84 (4) (2019)
Shaun D Fontaine, Angelo D Santi, Ralph Reid, Philip C Smith, Gary W Ashley, Daniel V Santi
PLX038: a PEGylated prodrug of SN-38 independent of UGT1A1 activity. Cancer chemotherapy and pharmacology 85 (1) (2019)
Eric L Schneider, Brian R Hearn, Samuel J Pfaff, Ralph Reid, David G Parkes, Niels Vrang, Gary W Ashley, Daniel V Santi
A Hydrogel-Microsphere Drug Delivery System That Supports Once-Monthly Administration of a GLP-1 Receptor Agonist. ACS chemical biology 12 (8) (2017)